Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Tigecycline | Case report

A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale

Authors: Xiaoping Shi, Donghui Lao, Qing Xu, Xiaoyu Li, Qianzhou Lv

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

There have been no reports of tigecycline-associated drug-related liver injury (DILI) identified by histopathological assistance and causal assessment method. We reported the histopathological manifestations for the first time and described tigecycline-associated liver injury’s pattern, severity, duration, and outcome.

Case presentation

A 68-year-old male with post-liver transplantation was given high-dose tigecycline intravenously (loading dose 200 mg, followed by 100 mg every 12 h) combined with polymyxin B (50,000 units by aerosol inhalation every 12 h) for hospital-acquired pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. At the same time, tacrolimus was discontinued. Liver function was initially normal but started to decline on day 4 of tigecycline. Reducing the dose of tigecycline and resuming tacrolimus could not reverse the deterioration. Therefore, a liver puncture biopsy was performed for further diagnosis, with histopathological findings being cytotoxic injury. The updated RUCAM scale was used to evaluate the causal relationship between tigecycline and liver injury, with the result of 7 points indicating a “probable” causality grading. Methylprednisolone was initiated to treat DILI that was determined to be Grade 1 cholestatic injury. Total bilirubin and transaminase levels returned to normal on day 4 and 11 after tigecycline withdrawal, respectively. Monthly outpatient follow-up showed that the patient’s liver function stayed normal.

Conclusions

This case possessed a significant reference value for differential diagnosis and treatment prognosis of tigecycline-associated DILI. With early diagnosis and timely management, the tigecycline-associated DILI of this patient was successfully reversed.
Literature
1.
go back to reference Brink AJ, Bizos D, Boffard KD, Feldman C, Grolman DC, Pretorius J, Richards GA, Senekal M, Steyn E, Welkovic N. Guideline: appropriate use of tigecycline. South Afr Med J. 2010;100(6 Pt 2):388–94.CrossRef Brink AJ, Bizos D, Boffard KD, Feldman C, Grolman DC, Pretorius J, Richards GA, Senekal M, Steyn E, Welkovic N. Guideline: appropriate use of tigecycline. South Afr Med J. 2010;100(6 Pt 2):388–94.CrossRef
2.
go back to reference Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine. 2018;97(38):e12467.CrossRef Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine. 2018;97(38):e12467.CrossRef
3.
go back to reference Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine. 2018;97(8):e9961.CrossRef Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine. 2018;97(8):e9961.CrossRef
4.
go back to reference Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine. 2020;99(10):e19466.CrossRef Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine. 2020;99(10):e19466.CrossRef
5.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–61.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–61.CrossRef
6.
go back to reference Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.CrossRef Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.CrossRef
7.
go back to reference Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–101.CrossRef Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–101.CrossRef
8.
go back to reference Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett. 1999;9(10):1459–62.CrossRef Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett. 1999;9(10):1459–62.CrossRef
9.
go back to reference Potts J, Gordon SC. The burden of acute non-fulminant drug-induced liver disease in the United States. Gastroenterology. 2003;124(4):749.CrossRef Potts J, Gordon SC. The burden of acute non-fulminant drug-induced liver disease in the United States. Gastroenterology. 2003;124(4):749.CrossRef
10.
go back to reference Casella G, Villanacci V, Di Bella C, Drera E, Baldini V, Bassotti G. Acute hepatitis caused by minocycline. Rev Esp Enferm Dig. 2010;102(11):668.CrossRef Casella G, Villanacci V, Di Bella C, Drera E, Baldini V, Bassotti G. Acute hepatitis caused by minocycline. Rev Esp Enferm Dig. 2010;102(11):668.CrossRef
11.
go back to reference de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103-12.e102.CrossRef de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103-12.e102.CrossRef
12.
go back to reference Chen Y, Zhu D, Zhang Y, Zhao Y, Chen G, Li P, Xu L, Yan P, Hickman MA, Xu X, et al. A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China. Ther Clin Risk Manag. 2018;14:2327–39.CrossRef Chen Y, Zhu D, Zhang Y, Zhao Y, Chen G, Li P, Xu L, Yan P, Hickman MA, Xu X, et al. A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China. Ther Clin Risk Manag. 2018;14:2327–39.CrossRef
13.
go back to reference Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hep Intl. 2017;11(3):221–41.CrossRef Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hep Intl. 2017;11(3):221–41.CrossRef
14.
go back to reference Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–98.CrossRef Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–98.CrossRef
15.
go back to reference Danan G, Teschke R. Roussel uclaf causality assessment method for drug-induced liver injury: present and future. Front Pharmacol. 2019;10:853.CrossRef Danan G, Teschke R. Roussel uclaf causality assessment method for drug-induced liver injury: present and future. Front Pharmacol. 2019;10:853.CrossRef
16.
go back to reference Gong J, Su D, Shang J, Yu H, Du G, Lin Y, Sun Z, Liu G. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis. Medicine. 2019;98(38):e17091.CrossRef Gong J, Su D, Shang J, Yu H, Du G, Lin Y, Sun Z, Liu G. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis. Medicine. 2019;98(38):e17091.CrossRef
17.
go back to reference Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Therapy. 2020;37(3):1049–64.CrossRef Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Therapy. 2020;37(3):1049–64.CrossRef
18.
go back to reference De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care (London England). 2014;18(3):R90.CrossRef De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care (London England). 2014;18(3):R90.CrossRef
19.
go back to reference Shi X, Zuo C, Yu L, Lao D, Li X, Xu Q, Lv Q. Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM. Front Pharmacol. 2021;12:761167.CrossRef Shi X, Zuo C, Yu L, Lao D, Li X, Xu Q, Lv Q. Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM. Front Pharmacol. 2021;12:761167.CrossRef
20.
go back to reference Fan G, Jin L, Bai H, Jiang K, Xie J, Dong Y. Safety and efficacy of tigecycline in Intensive Care Unit patients based on therapeutic drug monitoring. Ther Drug Monit. 2020;42(6):835–40.CrossRef Fan G, Jin L, Bai H, Jiang K, Xie J, Dong Y. Safety and efficacy of tigecycline in Intensive Care Unit patients based on therapeutic drug monitoring. Ther Drug Monit. 2020;42(6):835–40.CrossRef
21.
go back to reference Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73–96.CrossRef Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73–96.CrossRef
22.
go back to reference Vandecasteele SJ, Seneca S, Smet J, Reynders M, De Ceulaer J, Vanlander AV, van Coster R. Tigecycline-induced inhibition of mitochondrial DNA translation may cause lethal mitochondrial dysfunction in humans. Clin Microbiol Infect. 2018;24(4):431-e1.CrossRef Vandecasteele SJ, Seneca S, Smet J, Reynders M, De Ceulaer J, Vanlander AV, van Coster R. Tigecycline-induced inhibition of mitochondrial DNA translation may cause lethal mitochondrial dysfunction in humans. Clin Microbiol Infect. 2018;24(4):431-e1.CrossRef
Metadata
Title
A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale
Authors
Xiaoping Shi
Donghui Lao
Qing Xu
Xiaoyu Li
Qianzhou Lv
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Tigecycline
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07258-w

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue